151 related articles for article (PubMed ID: 3126278)
1. Metabolites of 6-[18F]fluoro-L-dopa in human blood.
Firnau G; Sood S; Chirakal R; Nahmias C; Garnett ES
J Nucl Med; 1988 Mar; 29(3):363-9. PubMed ID: 3126278
[TBL] [Abstract][Full Text] [Related]
2. The distribution and kinetics of [18F]6-fluoro-3-O-methyl-L-dopa in the human brain.
Wahl L; Chirakal R; Firnau G; Garnett ES; Nahmias C
J Cereb Blood Flow Metab; 1994 Jul; 14(4):664-70. PubMed ID: 8014214
[TBL] [Abstract][Full Text] [Related]
3. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography.
Melega WP; Grafton ST; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
J Cereb Blood Flow Metab; 1991 Nov; 11(6):890-7. PubMed ID: 1939384
[TBL] [Abstract][Full Text] [Related]
4. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.
Huang SC; Yu DC; Barrio JR; Grafton S; Melega WP; Hoffman JM; Satyamurthy N; Mazziotta JC; Phelps ME
J Cereb Blood Flow Metab; 1991 Nov; 11(6):898-913. PubMed ID: 1939385
[TBL] [Abstract][Full Text] [Related]
5. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.
Kuwabara H; Cumming P; Reith J; Léger G; Diksic M; Evans AC; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):43-56. PubMed ID: 8417009
[TBL] [Abstract][Full Text] [Related]
6. Aromatic radiofluorination with [18F]fluorine gas: 6-[18F]fluoro-L-dopa.
Firnau G; Chirakal R; Garnett ES
J Nucl Med; 1984 Nov; 25(11):1228-33. PubMed ID: 6436449
[TBL] [Abstract][Full Text] [Related]
7. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate.
Firnau G; Sood S; Chirakal R; Nahmias C; Garnett ES
J Neurochem; 1987 Apr; 48(4):1077-82. PubMed ID: 3102690
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans.
Cumming P; Léger GC; Kuwabara H; Gjedde A
J Cereb Blood Flow Metab; 1993 Jul; 13(4):668-75. PubMed ID: 8314919
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.
Melega WP; Luxen A; Perlmutter MM; Nissenson CH; Phelps ME; Barrio JR
Biochem Pharmacol; 1990 Jun; 39(12):1853-60. PubMed ID: 2112915
[TBL] [Abstract][Full Text] [Related]
11. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography.
Hoffman JM; Melega WP; Hawk TC; Grafton SC; Luxen A; Mahoney DK; Barrio JR; Huang SC; Mazziotta JC; Phelps ME
J Nucl Med; 1992 Aug; 33(8):1472-7. PubMed ID: 1634937
[TBL] [Abstract][Full Text] [Related]
12. Enantioselective synthesis of 6-[fluorine-18]-fluoro-L-dopa from no-carrier-added fluorine-18-fluoride.
Lemaire C; Damhaut P; Plenevaux A; Comar D
J Nucl Med; 1994 Dec; 35(12):1996-2002. PubMed ID: 7989984
[TBL] [Abstract][Full Text] [Related]
13. High yield synthesis of 6-[18F]fluoro-L-dopa by regioselective fluorination of protected L-dopa with [18F]acetylhypofluorite.
Chaly T; Diksic M
J Nucl Med; 1986 Dec; 27(12):1896-901. PubMed ID: 3097278
[TBL] [Abstract][Full Text] [Related]
14. Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA.
Endres CJ; DeJesus OT; Uno H; Doudet DJ; Nickles JR; Holden JE
Front Biosci; 2004 Jan; 9():505-12. PubMed ID: 14766386
[TBL] [Abstract][Full Text] [Related]
15. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Barrio JR; Huang SC; Melega WP; Yu DC; Hoffman JM; Schneider JS; Satyamurthy N; Mazziotta JC; Phelps ME
J Neurosci Res; 1990 Dec; 27(4):487-93. PubMed ID: 2127807
[TBL] [Abstract][Full Text] [Related]
16. [Synthesis and determination for enantiomeric purity of 6-fluoro-L-DOPA].
Tang GH; Zhang L; Tang XL; Wang YX; Yin DZ
Yao Xue Xue Bao; 2001 Oct; 36(10):739-42. PubMed ID: 12579971
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat.
Cumming P; Ase A; Diksic M; Harrison J; Jolly D; Kuwabara H; Laliberté C; Gjedde A
Biochem Pharmacol; 1995 Sep; 50(7):943-6. PubMed ID: 7575677
[TBL] [Abstract][Full Text] [Related]
18. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
[TBL] [Abstract][Full Text] [Related]
19. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
Pauwels T; Dethy S; Goldman S; Monclus M; Luxen A
Eur J Pharmacol; 1994 May; 257(1-2):53-8. PubMed ID: 8082707
[TBL] [Abstract][Full Text] [Related]
20. No-carrier-added regioselective preparation of 6-[18F]fluoro-L-dopa.
Lemaire C; Guillaume M; Cantineau R; Christiaens L
J Nucl Med; 1990 Jul; 31(7):1247-51. PubMed ID: 2113943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
